ReviewProgress in cardiovascular diseases
Left ventricular hypertrophy and hypertension.
Review in Progress in cardiovascular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
178 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Assessing Myocardial Strain and Myocardial Work as a Marker for Hypertensive Heart Disease: A Meta-Analysis.Reviews in cardiovascular medicine · 2023Pooled it
- Prevalence of left ventricular hypertrophy in children and young people with primary hypertension: Meta-analysis and meta-regression.Frontiers in cardiovascular medicine · 2022Pooled it
- Assessing the causal role of hypertension on left atrial and left ventricular structure and function: A two-sample Mendelian randomization study.Frontiers in cardiovascular medicine · 2022Pooled it
- MRI Assessment of Cardiac Function and Morphology in Adult Patients With Growth Hormone Deficiency: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2022Pooled it
- Pharmacotherapy for hypertension-induced left ventricular hypertrophy.The Cochrane database of systematic reviews · 2021Pooled it
- Functional Significance of Cardiac Rehabilitation-Regulated Expression of Circulating MicroRNA-423-5p in Hypertensive Patients with Heart Failure with a Moderately Reduced Ejection Fraction.Anatolian journal of cardiology · 2022Trial
- The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.Journal of healthcare engineering · 2022Trial
- Exercise Training Across the Hypertensive Heart Disease Continuum: Clinical Evidence and Implications for Prescription.Journal of cardiovascular development and disease · 2026Review
- Predictors of echocardiographic abnormalities in asymptomatic individuals with increased cardiothoracic ratio detected on chest radiography.American heart journal plus : cardiology research and practice · 2026Article
- Green-Synthesized Gold Nanoparticles UsingPharmaceutics · 2026Article
- Preprocedural CALLY Index As a Novel Predictor of Pacemaker Requirement After Transcatheter Aortic Valve Replacement.CJC open · 2026Article
- Clinical implications of left anterior fascicular block for cardiac remodeling in hypertensive patients.Journal of echocardiography · 2026Article
- Effect of the geometry and severity of left ventricular hypertrophy on cardiovascular mortality in dialysis patients.Kidney research and clinical practice · 2026Article
- Left atrial dysfunction in different morphologic phenotypes of hypertrophic cardiomyopathy: a cardiac magnetic resonance feature tracking study.Quantitative imaging in medicine and surgery · 2026Article
- Micro-nanoplastics in Cardiovascular Disease: A Critical Update from Environmental Exposure to Clinical Implications.Cardiovascular toxicology · 2026Review
- Causal atlas on comorbidities in cardiomyopathy: a Mendelian randomization study of European ancestry.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- A risk assessment nomogram for cardiac remodeling in the multimorbid geriatric patients: a retrospective study.BMC geriatrics · 2026Article
- Relations of left ventricular mass and hypertrophy to cognitive function in urban dwelling African American and White adults.Neuropsychology · 2026Article
- Sex Differences in Hospitalizations in the 6 Months Before a Diagnosis of Transthyretin Amyloid Cardiomyopathy.JACC. Advances · 2026Article
- Cardiomyopathy in women with acromegaly: clinical characteristics and associated factors in a Colombian multicenter registry.Frontiers in endocrinology · 2026Article
118 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension (HTN) is a major modifiable risk factor for cardiovascular disease (CVD) morbidity and mortality. The left ventricle (LV) is a primary target for HTN end-organ damage. In addition to being a marker of HTN, LV geometrical changes: concentric remodeling, concentric or eccentric LV hypertrophy (LVH) are major independent risk factors for not only CVD morbidity and mortality but also for all-cause mortality and neurological pathologies. Blood pressure control with lifestyle changes and antihypertensive agents has been demonstrated to prevent and regress LVH. Herein, we provide a comprehensive review of literature on the relationship between HTN and LV geometry abnormalities with a focus on diagnosis, prognosis, pathophysiological mechanisms, and treatment approaches.
Indexed as
Identifiers
31759953What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.